Given that our data show that more than half the patients taking GLP-1 medications earn less than $40,000 per year, this presents a financial challenge
Gastrointestinal symptoms such as nausea, vomiting, diarrhea, constipation, and abdominal discomfort are dose-dependent and usually improve with slow titration
Japan Demand for GLP-1 receptor agonists in Japan is projected to rise at 6.4% CAGR through 2036
It is also helpful for people who find it hard to keep their weight down with lifestyle changes alone
Your healthcare provider can assess whether semaglutide is appropriate based on your health status, medical history, and specific treatment goals
The active ingredient is the same, the mechanism of action is identical, and expected weight loss results are equivalent